Biotechs Stumble Following $145M In Pricings
Two more biotechs mounted their initial public offerings Thursday amid a continued warming of the market following a chilly January for IPOs, but were met with a weak reception by investors....To view the full article, register now.
Already a subscriber? Click here to view full article